New species-related MIC breakpoints for early detection of development of resistance among Gram-negative bacteria in Swedish intensive care units
Open Access
- 1 November 1999
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 44 (5) , 611-619
- https://doi.org/10.1093/jac/44.5.611
Abstract
The frequency of decreased antibiotic susceptibility among 534 Gram-negative aerobic bacilli from patients admitted to intensive care units at eight hospitals in Sweden during 1997 was evaluated. MICs of cefepime, ceftazidime, ceftriaxone, ciprofloxacin, gentamicin, imipenem and piperacillin–tazobactam were determined using Etest. Reduced susceptibility (resistant and intermediate/indeterminate susceptible strains) was defined according to the MIC breakpoints of the British Society for Antimicrobial Chemotherapy (BSAC), the National Committee for Clinical Laboratory Standards (NCCLS) and the new species-related breakpoints of the Swedish Reference Group for Antibiotics (SRGA). The BSAC/NCCLS/SRGA breakpoints for susceptible category (mg/L) of Enterobacteriaceae are: cefepime, not available (NA)/8/0.5; ceftazidime, 2/8/2; ceftriaxone, NA/8/0.5; ciprofloxacin, 1/1/0.12; gentamicin, 1/4/2; imipenem, 4/4/1; and piperacillin–tazobactam, NA/16/16. The most frequently isolated organisms were Escherichia coli (n = 160; 30%), Klebsiella spp. (n = 84; 16%), Enterobacter spp. (n = 77; 14%), Pseudomonas aeruginosa (n = 64; 12%) andProteus spp. (n = 28; 5%). Decreased susceptibility among E. coliusing the BSAC/NCCLS/SRGA respective breakpoints (%) were: cefepime, NA/0/2; ceftazidime, 2/2/2; ceftriaxone, NA/1/2; ciprofloxacin, 2/2/8; gentamicin, 21/0/3; imipenem, 0/0/2; and piperacillin-tazobactam, NA/4/4. Corresponding levels of decreased susceptibility (%) among Klebsiellaspp. were: cefepime, NA/0/5; ceftazidime, 2/1/2; ceftriaxone, NA/1/10; ciprofloxacin, 4/4/19; gentamicin, 25/2/5; imipenem, 0/0/0; and piperacillin-tazobactam, NA/10/10; and among Enterobacter spp. were: cefepime, NA/1/19; ceftazidime, 30/29/30; ceftriaxone, NA/30/36; ciprofloxacin, 3/3/15; gentamicin,18/0/0; imipenem, 0/0/5; and piperacilllin-tazobactam, NA/27/27. In conclusion, the species-related SRGA breakpoints detected Gram-negative isolates with decreased susceptibility in comparison with the native population with higher frequency than did the NCCLS breakpoints. The BSAC breakpoints for susceptible organisms were similar to NCCLS for ciprofloxacin and imipenem, and similar to SRGA for ceftazidime but lower than both NCCLS and SRGA for gentamicin, causing a much higher frequency of decreased susceptibility to gentamicin.Keywords
This publication has 18 references indexed in Scilit:
- Antibiotic Susceptibility Among Aerobic Gram-negative Bacilli in Intensive Care Units in 5 European CountriesJAMA, 1999
- Decrease in antibiotic susceptibility or increase in resistance?Journal of Antimicrobial Chemotherapy, 1998
- Antibiotic susceptibility in aerobic gram-negative bacilli isolated in intensive care units in 39 French teaching hospitals (ICU study)Intensive Care Medicine, 1996
- Antimicrobial Resistance Rates Among Aerobic Gram-Negative Bacilli Recovered from Patients in Intensive Care Units: Evaluation of a National Postmarketing Surveillance ProgramClinical Infectious Diseases, 1996
- Antibiotic resistance and production of extended-spectrum β-Mactamases amongst Klebsiella spp. from intensive care units in EuropeJournal of Antimicrobial Chemotherapy, 1996
- beta-Lactamases in laboratory and clinical resistanceClinical Microbiology Reviews, 1995
- The Prevalence of Nosocomial Infection in Intensive Care Units in EuropeJAMA, 1995
- Infection control and prevention strategies in the ICUIntensive Care Medicine, 1994
- Epidemiology of nosocomial infections in adult intensive care unitsIntensive Care Medicine, 1994
- Evaluation of the E test, a novel method of quantifying antimicrobial activityJournal of Antimicrobial Chemotherapy, 1991